Annual Working Capital
$202.92 M
+$156.72 M+339.28%
December 31, 2023
Summary
- As of February 7, 2025, SUPN annual working capital is $202.92 million, with the most recent change of +$156.72 million (+339.28%) on December 31, 2023.
- During the last 3 years, SUPN annual working capital has fallen by -$182.39 million (-47.34%).
- SUPN annual working capital is now -47.34% below its all-time high of $385.31 million, reached on December 31, 2020.
Performance
SUPN Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
$348.50 M
+$66.15 M+23.43%
September 30, 2024
Summary
- As of February 7, 2025, SUPN quarterly working capital is $348.50 million, with the most recent change of +$66.15 million (+23.43%) on September 30, 2024.
- Over the past year, SUPN quarterly working capital has increased by +$186.67 million (+115.35%).
- SUPN quarterly working capital is now -24.92% below its all-time high of $464.16 million, reached on March 31, 2018.
Performance
SUPN Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
SUPN Working Capital Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +339.3% | +115.3% |
| 3 y3 years | -47.3% | +115.3% |
| 5 y5 years | -38.9% | +115.3% |
SUPN Working Capital Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.1% | +339.3% | at high | +415.6% |
| 5 y | 5-year | -47.3% | +339.3% | -19.6% | +415.6% |
| alltime | all time | -47.3% | +724.6% | -24.9% | +415.6% |
Supernus Pharmaceuticals Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $348.50 M(+23.4%) |
| Jun 2024 | - | $282.35 M(+22.9%) |
| Mar 2024 | - | $229.77 M(+13.2%) |
| Dec 2023 | $202.92 M(+339.3%) | $202.92 M(+25.4%) |
| Sep 2023 | - | $161.83 M(-5.3%) |
| Jun 2023 | - | $170.95 M(+12.6%) |
| Mar 2023 | - | $151.79 M(+228.6%) |
| Dec 2022 | $46.19 M(-83.9%) | $46.19 M(-174.4%) |
| Sep 2022 | - | -$62.10 M(-43.8%) |
| Jun 2022 | - | -$110.42 M(-138.9%) |
| Mar 2022 | - | $283.96 M(-0.8%) |
| Dec 2021 | $286.21 M(-25.7%) | $286.21 M(-34.0%) |
| Sep 2021 | - | $433.66 M(+21.9%) |
| Jun 2021 | - | $355.80 M(+3.1%) |
| Mar 2021 | - | $345.21 M(-10.4%) |
| Dec 2020 | $385.31 M(+23.5%) | $385.31 M(+52.7%) |
| Sep 2020 | - | $252.41 M(-12.3%) |
| Jun 2020 | - | $287.88 M(-25.9%) |
| Mar 2020 | - | $388.71 M(+24.6%) |
| Dec 2019 | $312.06 M(-6.0%) | $312.06 M(+12.5%) |
| Sep 2019 | - | $277.37 M(+12.3%) |
| Jun 2019 | - | $246.94 M(-7.9%) |
| Mar 2019 | - | $268.26 M(-19.2%) |
| Dec 2018 | $332.13 M(+215.0%) | $332.13 M(+31.7%) |
| Sep 2018 | - | $252.21 M(+39.7%) |
| Jun 2018 | - | $180.58 M(-61.1%) |
| Mar 2018 | - | $464.16 M(+340.2%) |
| Dec 2017 | $105.45 M | $105.45 M(+22.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $86.37 M(+8.0%) |
| Jun 2017 | - | $79.97 M(+18.0%) |
| Mar 2017 | - | $67.75 M(-4.1%) |
| Dec 2016 | $70.66 M(+44.2%) | $70.66 M(+6.2%) |
| Sep 2016 | - | $66.56 M(+37.0%) |
| Jun 2016 | - | $48.57 M(+21.9%) |
| Mar 2016 | - | $39.83 M(-18.7%) |
| Dec 2015 | $49.01 M(-39.2%) | $49.01 M(-17.5%) |
| Sep 2015 | - | $59.42 M(-14.3%) |
| Jun 2015 | - | $69.33 M(-7.1%) |
| Mar 2015 | - | $74.65 M(-7.4%) |
| Dec 2014 | $80.60 M(+13.9%) | $80.60 M(-0.3%) |
| Sep 2014 | - | $80.84 M(+53.1%) |
| Jun 2014 | - | $52.79 M(-0.1%) |
| Mar 2014 | - | $52.83 M(-25.3%) |
| Dec 2013 | $70.76 M(+3.3%) | $70.76 M(-9.0%) |
| Sep 2013 | - | $77.79 M(-17.8%) |
| Jun 2013 | - | $94.59 M(+91.8%) |
| Mar 2013 | - | $49.32 M(-28.0%) |
| Dec 2012 | $68.48 M(+123.6%) | $68.48 M(+78.8%) |
| Sep 2012 | - | $38.30 M(-31.5%) |
| Jun 2012 | - | $55.92 M(+202.2%) |
| Mar 2012 | - | $18.50 M(-39.6%) |
| Dec 2011 | $30.63 M(+24.5%) | $30.63 M(+264.6%) |
| Sep 2011 | - | $8.40 M(-65.9%) |
| Dec 2010 | $24.61 M(-60.8%) | $24.61 M(-27.3%) |
| Sep 2010 | - | $33.84 M(-46.2%) |
| Dec 2009 | $62.85 M(+2.7%) | $62.85 M |
| Dec 2008 | $61.18 M | - |
FAQ
- What is Supernus Pharmaceuticals annual working capital?
- What is the all time high annual working capital for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual working capital year-on-year change?
- What is Supernus Pharmaceuticals quarterly working capital?
- What is the all time high quarterly working capital for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly working capital year-on-year change?
What is Supernus Pharmaceuticals annual working capital?
The current annual working capital of SUPN is $202.92 M
What is the all time high annual working capital for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual working capital is $385.31 M
What is Supernus Pharmaceuticals annual working capital year-on-year change?
Over the past year, SUPN annual working capital has changed by +$156.72 M (+339.28%)
What is Supernus Pharmaceuticals quarterly working capital?
The current quarterly working capital of SUPN is $348.50 M
What is the all time high quarterly working capital for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly working capital is $464.16 M
What is Supernus Pharmaceuticals quarterly working capital year-on-year change?
Over the past year, SUPN quarterly working capital has changed by +$186.67 M (+115.35%)